Innovative Product Pipeline ACELYRIN, INC. is actively developing next-generation targeted therapies such as envudeucitinib and ESK-001, showing a strong focus on immunotherapy and dermatology treatments, which presents opportunities to collaborate or supply complementary biotech solutions.
Strategic Collaborations Partnership with Kaken for ESK-001 development highlights ACELYRIN's openness to international collaborations in dermatology, opening doors for sales of research tools, clinical trial support, and application partners.
Recent Clinical Advancements Positive Phase 2 and Phase 3 trial results and upcoming presentations at major dermatology conferences suggest the company is rapidly advancing toward regulatory approval, providing an opportunity to support product launches or clinical trial services.
Growing Market Presence Participation in high-profile industry events like the AAD Annual Meeting and ACTRIMS Forum indicates increasing visibility in dermatology and immunology markets, ideal for positioning new or complementary biotech solutions.
Financial Growth Potential With a substantial funding of 300 million dollars and revenue estimates between 10 to 25 million dollars, ACELYRIN is positioned for expansion in the biotech sector, suggesting opportunities for investors, suppliers, and strategic partners seeking high-growth collaborations.
ACELYRIN, INC. uses 8 technology products and services including SAS Macro, GDPR, Oracle Argus, and more. Explore ACELYRIN, INC.'s tech stack below.
| ACELYRIN, INC. Email Formats | Percentage |
| First.Last@acelyrin.com | 97% |
| First@acelyrin.com | 2% |
| FLast@acelyrin.com | 1% |
| FLast@alumis.com | 100% |
Biotechnology ResearchCalifornia, United States11-50 Employees
ACELYRIN, INC. is a biotechnology research company based in Calabasas, California. It is now part of Alumis, reflecting a corporate integration within the Alumis organization. The firm operates with a small to mid-sized team. Public reporting indicates Alumis is pursuing a pipeline of oral TYK2 inhibitors for immune-mediated diseases, a focus that now encompasses ACELYRIN through its integration.
Company Overview
Media & News
Funding & FinancialsACELYRIN, INC. has raised a total of $300M of funding over 3 rounds. Their latest funding round was raised on Sep 13, 2022 in the amount of $300M.
ACELYRIN, INC.'s revenue is estimated to be in the range of $10M$25M
Funding & FinancialsACELYRIN, INC. has raised a total of $300M of funding over 3 rounds. Their latest funding round was raised on Sep 13, 2022 in the amount of $300M.
ACELYRIN, INC.'s revenue is estimated to be in the range of $10M$25M
1-888-653-2347 
support@leadiq.com